Literature DB >> 15151842

[Induced differentiation of human peripheral blood CD68+ mononuclear cells into osteoclasts in vitro].

Run-ming Zeng1, Da-di Jin, Zhong-min Zhang.   

Abstract

OBJECTIVE: To establish a method for obtaining highly purified primary human osteoclast precursors for the biochemical and molecular biological research.
METHODS: CD68(+) mono/macrophages were separated from peripheral blood mononuclear cells (PBMCs) of healthy donors by means of immunomagnetic cell sorting for subsequent analysis with flow cytometry. The isolated cells were incubated on coverslips or bone slices in the presence of dexamethasone(10(-8) mol/L), macrophage colony-stimulating factor (25 microg/L ) and soluble receptor activator of nuclear factor (NF)-kappaB ligand (s-RANKL, 16 microg/L). Calcitonin receptor (CR) immunocytochemistry and tartrate-resistant acid phosphatase (TRAP) histochemistry were employed. The bone slices were also studied by scanning electron microscopy (SEM).
RESULTS: Fluorescence-activated cytometric analysis showed that 93.06%+/-0.61% n=4 of the selected cells were CD68(+) cells. After 7 days of culture of the CD68(+) cells, VR+, TRAP+ multinucleated giant cells appeared, and resorption lacunae could be observed by SEM.
CONCLUSION: Highly purified CD68(+) cells can be obtained from human PBMCs as the osteoclast precursors, and mature osteoclasts can be induced from CD68(+) mono/macrophages by RANKL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15151842

Source DB:  PubMed          Journal:  Di Yi Jun Yi Da Xue Xue Bao        ISSN: 1000-2588


  2 in total

1.  Osteoclast precursors do not express CD68: results from CD68 promoter-driven RANK transgenic mice.

Authors:  Melissa F Jackson; Marta Scatena; Cecilia M Giachelli
Journal:  FEBS Lett       Date:  2017-02-20       Impact factor: 4.124

Review 2.  The multi-differentiation potential of peripheral blood mononuclear cells.

Authors:  Min Zhang; Bing Huang
Journal:  Stem Cell Res Ther       Date:  2012-11-30       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.